# Amyotrophic Lateral Sclerosis (ALS) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als

> 2 upcoming FDA catalysts in amyotrophic Lateral Sclerosis (ALS): COYA-302 (COYA) on April 2027 (primary completion); COYA-302 (COYA) on Apr to Jul 2027 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 23, 2026 | [VHB937 primary completion](https://sec-api.dev/pdufa/vhb937) | NVS | Amyotrophic Lateral Sclerosis (ALS) | completed | "NCT06643481 (A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643481)) |
| April 2027 | [COYA-302 primary completion](https://sec-api.dev/pdufa/coya-302) | COYA | Amyotrophic Lateral Sclerosis (ALS) | scheduled | "NCT07161999 (Study of COYA 302 for the Treatment of ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Coya Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07161999)) |
| Apr to Jul 2027 | [COYA-302 topline data readout](https://sec-api.dev/pdufa/coya-302) | COYA | Amyotrophic Lateral Sclerosis (ALS) | scheduled | "NCT07161999 (Study of COYA 302 for the Treatment of ALS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Coya Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07161999)) |

## Drugs

- [VHB937](https://sec-api.dev/pdufa/vhb937) (NVS)
- [COYA-302](https://sec-api.dev/pdufa/coya-302) (COYA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Amyotrophic Lateral Sclerosis (ALS) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als

```bibtex
@misc{secapidev_indications_amyotrophic_lateral_sclerosis_als_20261116,
  title        = {Amyotrophic Lateral Sclerosis (ALS) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_amyotrophic_lateral_sclerosis_als_20261116","title":"Amyotrophic Lateral Sclerosis (ALS) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/amyotrophic-lateral-sclerosis-als","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
